449 related articles for article (PubMed ID: 28807936)
1. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.
Schwaederle M; Chattopadhyay R; Kato S; Fanta PT; Banks KC; Choi IS; Piccioni DE; Ikeda S; Talasaz A; Lanman RB; Bazhenova L; Kurzrock R
Cancer Res; 2017 Oct; 77(19):5419-5427. PubMed ID: 28807936
[TBL] [Abstract][Full Text] [Related]
2. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
[TBL] [Abstract][Full Text] [Related]
4. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Banks KC; Lanman RB; Talasaz A; Parker BA; Kurzrock R
Oncotarget; 2016 Mar; 7(9):9707-17. PubMed ID: 26848768
[TBL] [Abstract][Full Text] [Related]
5. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Patel SP; Harismendy O; Ikeda M; Parker BA; Kurzrock R
Clin Cancer Res; 2016 Nov; 22(22):5497-5505. PubMed ID: 27185373
[TBL] [Abstract][Full Text] [Related]
6. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer.
Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H
Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757
[No Abstract] [Full Text] [Related]
7. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
8. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.
Schwaederlé MC; Patel SP; Husain H; Ikeda M; Lanman RB; Banks KC; Talasaz A; Bazhenova L; Kurzrock R
Clin Cancer Res; 2017 Sep; 23(17):5101-5111. PubMed ID: 28539465
[No Abstract] [Full Text] [Related]
9. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
10. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
11. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
12. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
13. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
[TBL] [Abstract][Full Text] [Related]
14. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
15. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
16. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
